GH Guardant Health, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1576280 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.0%
TTM net income YoY9.0%
TTM EPS YoY16.8%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—
Margins
Gross margin60.8%
Operating margin-60.0%
Net margin-59.0%
FCF margin-37.2%
EBITDA margin-54.4%
Returns
ROE-4,584.5%
ROA-26.7%
ROIC (approx.)—
Asset turnover0.45x
Leverage & solvency
Liabilities / assets109.4%
Debt / equity—
Current ratio4.68x
Interest coverage-171.87x
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $982.02M | $739.02M |
| Cost of revenue | $349.01M | $289.80M |
| Gross profit | $633.01M | $449.22M |
| R&D expense | $364.19M | $347.75M |
| SG&A expense | $211.41M | $180.12M |
| Operating income | -$437.25M | -$443.59M |
| Interest expense | $3.90M | $2.58M |
| Pretax income | -$417.54M | -$435.09M |
| Income tax | -$1.26M | $1.28M |
| Net income | -$416.28M | -$436.37M |
| EBITDA | -$397.51M | -$401.21M |
| EPS (basic) | -3.32 | -3.56 |
| EPS (diluted) | -3.32 | -3.56 |
| Weighted avg. shares (diluted) | 125.37M | 122.75M |
| Balance sheet | ||
| Cash & equivalents | $378.20M | $629.75M |
| Short-term investments | $823.39M | $314.44M |
| Receivables | $137.85M | $110.25M |
| Inventory | $85.88M | $71.08M |
| Current assets | $1.47B | $1.06B |
| PP&E, net | $145.91M | $136.81M |
| Goodwill | $77.26M | $3.29M |
| Intangibles | $25.92M | $6.76M |
| Total assets | $2.01B | $1.49B |
| Current liabilities | $302.73M | $225.58M |
| Long-term debt | $1.50B | $1.14B |
| Total debt | $1.50B | $1.14B |
| Total liabilities | $2.11B | $1.63B |
| Shareholders' equity | -$99.31M | -$139.65M |
| Net debt | $1.13B | $512.79M |
| Shares outstanding | 130.64M | 123.99M |
| Cash flow statement | ||
| Operating cash flow | -$184.76M | -$239.86M |
| Capital expenditure | $48.31M | $35.09M |
| Free cash flow | -$233.07M | -$274.94M |
| Investing cash flow | -$627.20M | -$261.31M |
| Financing cash flow | $671.13M | -$996,000 |
| Depreciation & amortization | $39.74M | $42.39M |
| Stock-based compensation | $166.22M | $140.41M |
| Share buybacks | $45.01M | $0 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.